Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate

Nephrology

Volumn 12, Issue 1, 2007, Pages 111-

  Hedley, Adam J ^a   Molan, Maurice P ^a   Hare, David L ^a   Anavekar, Nagesh S ^a   Ierino, Francesco L ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

GLOMERULUS FILTRATION RATE; HUMAN; LETTER; NEPHROGENIC FIBROSING DERMOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY;

EID: 33846992683     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00751.x     Document Type: Letter

References (3)

1. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrastenhanced magnetic resonance imaging. J. Am. Soc. Nephrol. 2006; 17: 2359-62.
2. Grobner T. Gadolinium - A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol. Dial Transplant 2006; 24: 1104-8.
3. United States Food and Drug Administration [homepage on the Internet]. Rockville, Maryland, USA: United States Food and Drug Administration [created 8 June 2006, cited 3 October 2006]. Public Health Advisory Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance and MultiHance. Available from URL: http://www.fda.gov/cder/ drug/advisory/gadolinium_agents.htm.